Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical, Inc. (Nasdaq: OM) has appointed Steve Williamson as Chief Commercial Officer to lead its commercial and service organizations, enhancing adoption of the Tablo Hemodialysis System. Under Williamson's leadership, the company experiences meaningful growth in health systems and received FDA clearance for home use. With over two decades in the medical technology field, including significant revenue growth at BD, Williamson aims to reduce dialysis costs and complexity, improving patient experiences.
Outset Medical, Inc. (Nasdaq: OM) plans to release its third-quarter 2020 financial results on November 11, 2020, after the market closes. Following the release, CEO Leslie Trigg and CFO Rebecca Chambers will host a conference call at 2:00 PM PT (5:00 PM ET) to discuss the results. Outset is known for its innovative Tablo Hemodialysis System, designed to simplify dialysis processes and reduce costs. This technology has been FDA cleared for both hospital and home use, streamlining patient care significantly.